Ginkgo and AD

[Guest guest]

Interesting study on Ginkgo slowing progression of AD.

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1468-1331.2006.01409.x

Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study

M. Mazzaa, A. Capuanob, P. Briaa and S. Mazzab

The Ginkgo biloba special extract EGb 761 seems to produce neuroprotective effects in neurodegenerative diseases of multifactorial origin. There is still debate about the efficacy of Ginkgo biloba special extract EGb 761 compared with second-generation cholinesterase inhibitors in the treatment of mild to moderate Alzheimer's dementia. Our aim is to assess the efficacy of the Ginkgo biloba special extract E.S. in patients with dementia of the Alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment compared with donepezil and placebo. The trial was designed as a 24-week randomized, placebo-controlled, double-blind study. Patients aged 50–80 years, suffering from mild to moderate dementia, were allocated into one of the three treatments: Ginkgo biloba (160 mg daily dose), donepezil (5 mg daily dose), or placebo group. The degree of severity of dementia was assessed by the Syndrom Kurz test and the Mini-Mental State Examination. Clinical Global Impression score was recorded to assess the change in the patients' conditions and the therapeutic efficacy of tested medications. Our results confirm the clinical efficacy of Ginkgo biloba E.S. (Flavogin) in the dementia of the Alzheimer type, comparable with donepezil clinical efficacy. There are few published trials that have directly compared a cholinesterase inhibitor with Ginkgo for dementia. This study directly compares a cholinesterase inhibitor with Ginkgo biloba for dementia of the Alzheimer type and could be a valid contribution in this debate. Our study suggests that there is no evidence of relevant differences in the efficacy of EGb 761 and donepezil in the treatment of mild to moderate Alzheimer's dementia, so the use of both substances can be justified. In addition, this study contributes to establish the efficacy and tolerability of the Ginkgo biloba special extract E.S. in the dementia of the Alzheimer type with special respect to moderately severe stages.

Found it linked off of http://www.mercola.com/2006/dec/9/more-evidence-ginkgo-biloba-works-just-as-well-as-dementia-drugs.htm .

Qadoshyah

[Guest guest]

Did you post this to

DSTNI?

kathyR

From: Down Syndrome Treatment

[mailto:Down Syndrome Treatment ] On Behalf Of Qadoshyah

Sent: Sunday, December 10, 2006

5:39 PM

To:

Down Syndrome Treatment ; 'Providing hope for those who love

someone with Down Syndrome (Down's syndrome)'

Subject:

Ginkgo and AD

Interesting

study on Ginkgo slowing progression of AD.

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1468-1331.2006.01409.x

Ginkgo biloba and donepezil: a comparison

in the treatment of Alzheimer's dementia in a randomized placebo-controlled

double-blind study

M. Mazzaa, A. Capuanob,

P. Briaa and S. Mazzab

The Ginkgo biloba special extract EGb 761 seems

to produce neuroprotective effects in neurodegenerative diseases of

multifactorial origin. There is still debate about the efficacy of Ginkgo

biloba special extract EGb 761 compared with second-generation cholinesterase

inhibitors in the treatment of mild to moderate Alzheimer's dementia. Our aim

is to assess the efficacy of the Ginkgo biloba special extract E.S. in

patients with dementia of the Alzheimer type in slowing down the disease's

degenerative progression and the patients' cognitive impairment compared with

donepezil and placebo. The trial was designed as a 24-week randomized,

placebo-controlled, double-blind study. Patients aged 50–80 years,

suffering from mild to moderate dementia, were allocated into one of the

three treatments: Ginkgo biloba (160 mg daily dose), donepezil (5 mg

daily dose), or placebo group. The degree of severity of dementia was

assessed by the Syndrom Kurz test and the Mini-Mental State Examination.

Clinical Global Impression score was recorded to assess the change in the

patients' conditions and the therapeutic efficacy of tested medications. Our

results confirm the clinical efficacy of Ginkgo biloba E.S. (Flavogin) in the

dementia of the Alzheimer type, comparable with donepezil clinical efficacy.

There are few published trials that have directly compared a cholinesterase

inhibitor with Ginkgo for dementia. This study directly compares a

cholinesterase inhibitor with Ginkgo biloba for dementia of the Alzheimer

type and could be a valid contribution in this debate. Our study suggests

that there is no evidence of relevant differences in the efficacy of EGb 761

and donepezil in the treatment of mild to moderate Alzheimer's dementia, so

the use of both substances can be justified. In addition, this study

contributes to establish the efficacy and tolerability of the Ginkgo biloba

special extract E.S. in the dementia of the Alzheimer type with special

respect to moderately severe stages.

Found it

linked off of http://www.mercola.com/2006/dec/9/more-evidence-ginkgo-biloba-works-just-as-well-as-dementia-drugs.htm .

Qadoshyah

[Guest guest]

No, I did not. I can post it on there, but I don't know that it'll go up on the list. When I do post things on there, they don't seem to go up on the list for awhile. Would you mind posting it? Or, I can post it and we'll just see when it goes up.

Qadoshyah

*Got Down Syndrome?

www.gotdownsyndrome.net

From: Down Syndrome Treatment [mailto:Down Syndrome Treatment ] On Behalf Of Kathy RatkiewiczSent: Monday, December 11, 2006 8:21 AMDown Syndrome Treatment Subject: RE: Ginkgo and AD

Did you post this to DSTNI?

kathyR

From: Down Syndrome Treatment [mailto:Down Syndrome Treatment ] On Behalf Of QadoshyahSent: Sunday, December 10, 2006 5:39 PMDown Syndrome Treatment ; 'Providing hope for those who love someone with Down Syndrome (Down's syndrome)'Subject: Ginkgo and AD

Interesting study on Ginkgo slowing progression of AD.

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1468-1331.2006.01409.x

Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study

M. Mazzaa, A. Capuanob, P. Briaa and S. Mazzab

The Ginkgo biloba special extract EGb 761 seems to produce neuroprotective effects in neurodegenerative diseases of multifactorial origin. There is still debate about the efficacy of Ginkgo biloba special extract EGb 761 compared with second-generation cholinesterase inhibitors in the treatment of mild to moderate Alzheimer's dementia. Our aim is to assess the efficacy of the Ginkgo biloba special extract E.S. in patients with dementia of the Alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment compared with donepezil and placebo. The trial was designed as a 24-week randomized, placebo-controlled, double-blind study. Patients aged 50–80 years, suffering from mild to moderate dementia, were allocated into one of the three treatments: Ginkgo biloba (160 mg daily dose), donepezil (5 mg daily dose), or placebo group. The degree of severity of dementia was assessed by the Syndrom Kurz test and the Mini-Mental State Examination. Clinical Global Impression score was recorded to assess the change in the patients' conditions and the therapeutic efficacy of tested medications. Our results confirm the clinical efficacy of Ginkgo biloba E.S. (Flavogin) in the dementia of the Alzheimer type, comparable with donepezil clinical efficacy. There are few published trials that have directly compared a cholinesterase inhibitor with Ginkgo for dementia. This study directly compares a cholinesterase inhibitor with Ginkgo biloba for dementia of the Alzheimer type and could be a valid contribution in this debate. Our study suggests that there is no evidence of relevant differences in the efficacy of EGb 761 and donepezil in the treatment of mild to moderate Alzheimer's dementia, so the use of both substances can be justified. In addition, this study contributes to establish the efficacy and tolerability of the Ginkgo biloba special extract E.S. in the dementia of the Alzheimer type with special respect to moderately severe stages.

Found it linked off of http://www.mercola.com/2006/dec/9/more-evidence-ginkgo-biloba-works-just-as-well-as-dementia-drugs.htm .

Qadoshyah